Literature DB >> 2784308

HLA-DR and tuberculin tests in rheumatoid arthritis and tuberculosis.

G M Bahr1, M A Sattar, J L Stanford, M A Shaaban, B Al Shimali, Z Siddiqui, M Gabriel, M Al Saffar, A Shahin, T D Chugh.   

Abstract

Responses to four new tuberculins were found to be significantly reduced in 46 patients with rheumatoid arthritis in comparison with a control group of 79. Except for tuberculin itself, the same was found in 111 patients with tuberculosis. In common with patients with tuberculosis and leprosy, those with rheumatoid arthritis did not respond to common mycobacterial (group i) antigen. Three DR haplotypes were found to have significant effects on skin test responsiveness of the rheumatoid patients but had little or no effect on that of the patients with tuberculosis and none on that of the healthy control group. Rheumatoid patients with the HLA-DR4 haplotype had significantly greater responses to all four reagents than did non-DR4 patients, but their responses to leprosin A and scrofulin remained significantly lower than those of the control group. Possession of HLA-DR3 haplotype was associated with skin test positivity approaching normal, but the sizes of responses were reduced. Possession of DR7 was associated with an unexpected reduction in skin test positivity, especially in the case of tuberculin. These results support the hypothesis that mycobacteria, or autoantigens cross reactive with mycobacteria, may be involved in the aetiology of rheumatoid arthritis. The results also show that the regulation and specificity of responsiveness to mycobacterial antigens are different in patients with rheumatoid arthritis with different HLA-DR haplotypes.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2784308      PMCID: PMC1003677          DOI: 10.1136/ard.48.1.63

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  18 in total

1.  The meaning and structure of species as applied to mycobacteria.

Authors:  J L Stanford; J M Grange
Journal:  Tubercle       Date:  1974-06

2.  Simultaneous detection of two cell populations by two-colour fluorescence and application to the recognition of B-cell determinants.

Authors:  J J van Rood; A van Leeuwen; J S Ploem
Journal:  Nature       Date:  1976-08-26       Impact factor: 49.962

3.  A preliminary investigation of the responsiveness or otherwise of patients and staff of a leprosy hospital to groups of shared or species antigens of mycobacteria.

Authors:  J L Stanford; P M Nye; G A Rook; N Samuel; A Fairbank
Journal:  Lepr Rev       Date:  1981-12       Impact factor: 0.537

4.  Low T lymphocyte responsiveness to Mycobacterium leprae antigens in association with HLA-DR3.

Authors:  W van Eden; B G Elferink; R R de Vries; D L Leiker; J J van Rood
Journal:  Clin Exp Immunol       Date:  1984-01       Impact factor: 4.330

5.  HLA-DR-associated genetic control of the type of leprosy in a population from surinam.

Authors:  W van Eden; R R de Vries; J D'Amaro; I Schreuder; D L Leiker; J J van Rood
Journal:  Hum Immunol       Date:  1982-07       Impact factor: 2.850

6.  Arthritis induced in rats by cloned T lymphocytes responsive to mycobacteria but not to collagen type II.

Authors:  J Holoshitz; A Matitiau; I R Cohen
Journal:  J Clin Invest       Date:  1984-01       Impact factor: 14.808

7.  Lines of T lymphocytes induce or vaccinate against autoimmune arthritis.

Authors:  J Holoshitz; Y Naparstek; A Ben-Nun; I R Cohen
Journal:  Science       Date:  1983-01-07       Impact factor: 47.728

8.  Genetic basis of rheumatoid disease: HLA antigens, disease manifestations, and toxic reactions to drugs.

Authors:  G S Panayi; P Wooley; J R Batchelor
Journal:  Br Med J       Date:  1978-11-11

9.  HLA-DR3 associated genetic control of response to multiple skin tests with new tuberculins.

Authors:  W van Eden; R R de Vries; J L Stanford; G A Rook
Journal:  Clin Exp Immunol       Date:  1983-05       Impact factor: 4.330

10.  A further investigation of skin-test responsiveness and suppression in leprosy patients and healthy school children in Nepal.

Authors:  A Morton; P Nye; G A Rook; N Samuel; J L Stanford
Journal:  Lepr Rev       Date:  1984-09       Impact factor: 0.537

View more
  8 in total

Review 1.  The role of IgG glycoforms in the pathogenesis of rheumatoid arthritis.

Authors:  T W Rademacher; R B Parekh; R A Dwek; D Isenberg; G Rook; J S Axford; I Roitt
Journal:  Springer Semin Immunopathol       Date:  1988

2.  Skin test responsiveness to Mycobacterium tuberculosis, HLA-DR4, and rheumatoid arthritis.

Authors:  H M Markusse; J M Hazes; B A Dijkmans; R R de Vries; J L Stanford
Journal:  Ann Rheum Dis       Date:  1989-02       Impact factor: 19.103

Review 3.  A reappraisal of the evidence that rheumatoid arthritis and several other idiopathic diseases are slow bacterial infections.

Authors:  G A Rook; P M Lydyard; J L Stanford
Journal:  Ann Rheum Dis       Date:  1993-03       Impact factor: 19.103

4.  Rheumatoid arthritis in a population sample in the Gulf: clinical observations.

Authors:  H M al Attia; O B Gatee; S George; M M Masri
Journal:  Clin Rheumatol       Date:  1993-12       Impact factor: 2.980

5.  Clinical and laboratory studies of arthritis in leprosy.

Authors:  S L Atkin; A el-Ghobarey; M Kamel; J P Owen; W C Dick
Journal:  BMJ       Date:  1989-05-27

Review 6.  Rheumatoid arthritis: how well do the theories fit the evidence?

Authors:  J McCulloch; P M Lydyard; G A Rook
Journal:  Clin Exp Immunol       Date:  1993-04       Impact factor: 4.330

7.  Raised serum IgG and IgA antibodies to mycobacterial antigens in rheumatoid arthritis.

Authors:  G Tsoulfa; G A Rook; J D Van-Embden; D B Young; A Mehlert; D A Isenberg; F C Hay; P M Lydyard
Journal:  Ann Rheum Dis       Date:  1989-02       Impact factor: 19.103

8.  Membrane N-acetylglucosamine: expression by cells in rheumatoid synovial fluid, and by pre-cultured monocytes.

Authors:  M Sharif; L S Wilkinson; J Edwards; G A Rook
Journal:  Br J Exp Pathol       Date:  1989-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.